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Wc invcstigatcd thc binding properlies of thc (R)- and (Sl-cnantiomcrs of thc muscarinic antagonists trihcxyphcnidyl, 
procyclidinc, hcxahydro-difcnidol. p-fluoro-hcxahydro-difcnidol. hcxbutinol, p-fluoro-hcxbutinnl. and thcir corrcsponding mc-
thiodidcs at muscarinic M1• M 1• M~ and M 4 rcccptor subtypcs. In addition. binding properlies of thc (R)- and (S)-cnantiomcrs 
of oxyphcncycliminc wcrc studicd. Thc {R)- cnantiomcrs (cutomcrs} of all thc compounds had a grcatcr affinity than thc 
(S)-isomcrs for thc four muscarinic rcccptor subtypcs. Thc binding pattcrns of thc (R)- and (S)-cnantiomcrs wcrc gcncrally 
different. Wc did not obscrvc any gcncral corrclation hctwccn thc potcncy of thc high-affinity cnantiomcr and Lhc affinity ratio 
(cudismic ratio) of thc two cnantiomcrs. Thc rcsuhs arc discusscd in tcrms of a 'four suhsitcs' binding modcl. 
Muscarinic rcccptors; Hexahydro-difcnidol; Hcxbutinol; Oxyphcncycliminc: Eudismic ana!ysis; Pfciffcr's rulc; 
Stcrcosclcctivity; Rcccptm intcraction 
I. lntroduction 
At least four muscarinic rcceptors can now bc dis-
criminatcd in radioligand experiments (Lazarcno and 
Robcrts, 1989; Michel et al., 1989; Lazarcno et al., 
1990; Waelbroeck et aL, J990a) andin pharmacological 
studies (Dörje et al., 1990). using a battery of sclcctivc 
antagonists. The M 1 receptors have the highest affinity 
for pirenzepine (Hammer et al., 1980), the M 2 rcccp-
tors, the highest affinity for AF-DX 116 (Giachdli et 
al., 1986) and the MJ and M 4 receptors have highcr 
affinities than M 2 receptors for 4-diphenylacetoxy N-
methyl piperidine methiodide (4-DAMP) (Barlow et 
al., 1976) and for hexahydro-sila-difenidol (Mutschler 
and Lambrccht, 1984; Lambrecht et al., 1989). The 
cardioselectivc drugs himbacine (Gilani and Cobbing, 
1986) and methoctramine (Melchiorrc et al., 1987) can 
be used to discriminate them from each other, bccausc 
they have a highcr affinity for M 4 than M ~ reccptors. 
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Thc tissuc distribution and antagonist binding proper-
lies of thc M 1, M 2 , M ·' and M4 rcccptors arc compara-
ble to the tissue distribution of the m 1, m2, m3 and m4 
mcsscngcr RNAs and to thc binding properlies of thc 
corresponding cloncd rcccptors cxpressed in different 
ccll lincs (Bonncr. 1989; Lcvinc and Birdsall, l W~9; 
Dörjc ct al., 1991 ). 
In thc last few ycars, data havc becn accumulatcd 
suggcsting tlmt the muscarinic reccptor subtypcs can 
also bc diffcrcntiatcd on thc basi~ of thcir st~rcosdc~­
tivity (sec bclow ). A special vocabulary was introduced 
to dcscribc thcsc data (Lehmann, 1986). The enan-
tiomcr with thc highcr affinity for thc rcccptors is 
called thc ·eutomer', thc lcss affinitivc, thc 'distomcr'. 
Their affinity ratio ('cudismic ratio') is a mcasure of 
thc rcceptor's stcrcosclectivity. Its logarithm, thc 
'eudismic indcx'. is proportional to thc differencc bc-
tween the binding frec cncrgies of thc eutomcr and 
distomcr. Thc cudismic indcx of chirat muscarinic an-
tagonists, such as procyclidine (Lambrecht and 
Mutschler, 1986~ Tackc et al., 1986; Waclbroeck et al., 
J 990b), trihcxyphcnidyl and its mcthiodidc (Lambrecht 
et al., 1988), biperiden (Eitze and Figala, 1988), hcxa-
hydro-t.ifenidol and hexhutinol (Fcifel ct al.. J 990) as 
weil as telenzepinc ( Evcleigh ct al., J 989) has be~n 
used as an additional critcl: .J.n for rcceptor classifica-
tion. In thc case of muscarinic amagonists carrying a 
1,3-oxathiolane nucl!.!us. therc was also a dcar-eut dif-
fcrence bctween the cudismic affinity quoticnt (which 
measures the variation of thc cudismic index with 
cutomcr affinity) whcn comparing the muscarinic rc-
ceptors in thc hcart, biadder or iieum (Gucilti(;ri d (iL, 
1990), supporting thc hypothesis that thcse reccptors 
arc different. 
We compared in this work thc attm1ty and stercose-
lectivity of the enantiomers of scveral tcrtiary and 
quaternary chiral antagonists (sec fig. I), all posscssing 
a hydroxy, phcnyl, and cyclohexyl group bound to the 
centre of chirality, but diffcring in thc structurc of thc 
basic amino (ammonium) group and thc structurc of 
the chain connecting the carbinol carbon atom and thc 
cationic hcad (fig. 1). In addition. four analogues with 
a para-fluoro-phenyl rather than phcnyl group (fig. J) 
were invcstigated. Affinity data were obtaincd in com-
petition experiments using [ ·'H]N-mcthyl scopolaminc 
as radioligand. Thc reccptors studicd were thc NB~OK 
1 ncuroblastoma (M 1 ). rat cardiac (M 2 ), and pancrcas 
(i\! 3) reccptors, and the rat striatum receptors with M 4 
binding propertic:;. Our goals wcrc 2-fold: (a) tcst the 
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hypothesis that the receptor's stereoselectivity or eu-
dismic affinity quotient can be used in combination 
with affinity valucs for reccptor classification; (b) ob-
tam a better understanding of the basis of enantiomer 
discrimin~Hion by muscarinic receptors (binciing model). 
The functional properties of the enantiomers of 
trihexyphenidyl (compound 1 in fig. 1) and its mcthio-
didc (2) (L~r«biC'-~i~ ~~ al., 198~}. procyclidine (3) and 
tricyclamol (4) (Tacke ct al., 1986). hexahydm-difenidol 
(5) as weil as hcxbutinol (9), its methiodide (10) and 
p-fluoro-hexbutinoi ( i i) {Ft;ifd ci aL, 199G) tü ums~ 
carinic receptor subtypcs havc been reportcd else-
where. The binding affinities of the enantiomers of 
compounds 3 and 5-8 at muscarinic receptor subtypes 
havc also becn dcscribed (Waelbroeck et al., 1990b, 
199la,b). 
2. Materials and :nethods 
2.1. Ce/1 and tissue preparations 
Human NB-OK 1 neuroblastoma cells (a generous 
gift from Dr. Yanaihara, Shizuoka, Japan) werc main-
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Fig. I. Chemical structure of the compounds ( 1-13) invesligatcd in this study. 
penicillin, 100 J.Lgfml Streptomycin and IOC:'r foctal calf 
serum (from Gibco, Gent, Belgium). Twice a weck the 
ceHs were detachcd by trypsin-EDTA (Gibco. Gent. 
Belgium) and divided 1/3. For [JH)N-methyl scopol-
amine ([ 3H]NMS) binding experiments, the cells wcrc 
harvested using a 20 mM sodium phosphate buffcr 
enriched with 1 mM EDTA and 150 mM NaCI (pH 
7.4), centrifuged at 500 X g for 5 min, resuspended and 
homogenized in 20 mM Tris-HCI buffer enriched w!th 
5 mM MgCl 2 (pH 7.5) in a glass-Tetlon homogcnizcr, 
and then stored in liquid nitrogP.n until use. 
For cardiac homogenates male Wistar albino rats 
(200-250 g) were killcd by decapitation, and thc hcart 
was immediately removcd and rinsed in 150 mM NaCI. 
The homogenization buffer containcd 20 mM Tris-HCI 
(pH 7.5) and 250 mM sucrose. Each hcart was homogc-
nized in 2 ml of this buffer with :.n Ultraturrax homog-
enizcr (maximal speed for 5 ::. 4°C) followcd by 
further addition of 13 ml of buffer, and 7 up and down 
strokes in a glass-Teflon homogenizer (at 4°C). The 
homogenate was fittered on two layers of medical 
gauze and either used immediately or stored in !iquid 
nitrogen until use. 
For rat striatum homogenates thc brain was imme-
diately removed and dissected. The striatum was ho-
mogenized in 2 ml of 20 mM Tris-HCI buffer (pH 7.5) 
enriched with 250 mM sucrosc, with a glass-Tcflon 
homogenizer, and stored in liquid nitrogcn until usc. 
These homogenatcs were diluted 20-fold with the ho-
mogenization buffer before use for [ 3 H]NMS binding 
experiments. 
For rat pancreas homogcnates the organ was imme-
diately removed, minced with ~·issors and homogc-
nized in a glass-Tcflon homogenizer (7 up and down 
strokes at 4°C) in a solution containing 300 mM su-
crose, 0.2 mgjml bacitracin and 500 kallikrcin inhibitor 
U jml of Trasylol (Bayer, Brussels, Belgium). Thc re-
sulting homogenate was immediatcly fittered on two 
layers of medical gauze and diluted 11-fold with thc 
incubation buffer. 
2.2. / 3H/NMS binding experiments 
[ ~H]NMS binding was measured at 25°C in a total 
volume of 1.2 ml using thc following incubation buffcr: 
50 mM sodium phosphate (pH 7.4) enriched with 2 
mM MgCI 2, I% bovinc serum albumin (except when 
indicated) and the indicated tracer and drug concen-
trations. Addition of bovi:le serum albumin to thc 
incubation buffer increased [ 3H]NMS binding very 
slightly (by at most 10-15%) and improved the repro-
ducibility of duplicates in our filtration assays. In bind-
ing experiments on pancreas homogenates, we also 
addcd Trasylol and bacitracin (see above) to further 
inhibit proteolytic activity. Bovinc serum albumin was 
an essential ingredient in pancreas binding studies, 
sincc the binding capacity of pancrcao;; homogcnatcs 
disappcarcd within 40 min at room tcmpcraturc if this 
protcin was omittcJ from thc buffcr. hut was main-
tained over 9W/c for at least 4 h in its prcscncc. 
To terminatc thc incuhation, cach samplc was di-
luted with 2 ml of icc-cold 50 mM sodium rhosphatc 
buffcr (pH 7.4) and filtcrcd on GF/C glass-li.'re filters 
(\Vhatman. Maidstonc. UK) prcsoakcd in !Ul~r; 
polycthylcnimine. Thc filtcrs wcrc rinscJ 3 timcs with 
the samc filtration buffer. dried. and thc radioactivity 
(bound traccr) countcd hy liquid scintillation. Non-
spccific binding was dcfincd as l-'HjNMS bindmg m 
thc prescncc of 1 J.L M atropinc. 
For [ ::ll-l]NMS binding to human NB-OK 1 ccll ho-
mogcnatcs. a 0.25 nM tracer concentration l2-fold K I> 
for M 1 rcccptors) was choscn with a homogcnatc con-
centration of 160-200 J.Lg protcin pcr assay (ahout SO 
pM binding sitcs) and an incuhation pcriod of 2 h at 
25°C allowing full cquilibration of traccr binding. 
In binding cxpcrimcnts on rat cardiac homogcnatcs. 
a I nM [3 H]NMS concentration (2-fold Kl> at M2 
receptors) was selected with a homogcnatc conccntra-
tion of 400-500 J.Lg protcin pcr assay (about 250 pM 
binding sites) and a 2 h incubation pcriod at 25°C 
allowing full cquilibration of traccr binding. 
In binding cxpcrimcnts on rat striatum ho-
mogcnatcs, thc traccr conccntration w:1s 0.25 nM and 
the protein concentration 30-40 p.g pcr assay (ahout 
50 pM binding sites). Under equilibrium conditions (2 
h incubation :-tt 25°C) [ ~ H]NMS Iahelied M 1• M .~ and 
M-l sitc~ in this bn.tin rcgion. To analyzc traccr binding 
to M4 sitcs only. we preincubatcd striatum ho-
mogcnatcs for 2 h at :25°C to allow cquilihrium binding, 
thcn induccd traccr dissociation hy adding 1 J.LM at-
ropine. [ 3H]N MS dissm:iat~d from its hinding sitcs 
aftcr 35 min of isotopic dilution, thc residual binding 
bcing about 30\} of initial hinding. Sim:c [~H]NMS 
dis~tJciation from M 1 sitcs is fast er than that from M .~ 
and M4 sitcs. H5r,i of this residual [ ·~H]NMS hinding 
corrcspondcd to M4 binding sit,.!s <Waclhrocck ct al.. 
l990a). 
It is ncccssary to kccp traccr binding bclow Jsr;;. of 
thc total traccr addcd to avoid distortions of thc com-
petition cuJVcs duc to traccr or unlabclled drug dcplc-
tion. This mcans that thc residual traccr hinding to 
striatum M4 ( + M_.) sites in thc ahscncc of unlabcllcd 
drug must be maintaincd bclow srk. of thc total traccr 
added (i.c. 30%· of thc I5r;f· initial binding). Wc thcrc-
rorc dccidcd to usc a comparativcly high [ -'H]NMS 
conccntration (().25 nM, cquivatcnt to 5-fold K JJ at M 4 
sitcs) for thcse expcrim~nts. 
In binding cxpcrimcnts on rat pancrcas ho-
mogenates we used 9RO J.L I of the homogcn<ttc pcr 1.2 
ml samplc. Thc r'H]NMS conccntration v'a;o; 0.25 nM 
(2-fold Kn at M 3 rcccptors) and protcin concentration 
800-1000 J.Lg pcr assay ( ~blJut 50 pM binding sitcs ). An 
incubation pcriod of 4 h was nccc.~ssary to allow hinding 
cquilibrium. 
Protein conccntration was mcasurcd according to 
Lowry ct al. ( 1951) using bovinc scrum alhumin as 
standard. 
2.3. Dma analysis and statistics 
Thc compctition curvcs for unlabcllcd antagonists 
J- i 3 (fig. 1) wcrc analyzcd using the computcr pro~ 
gram dcscribcd by Richardson and Humrich ( Jl)g4), 
and wcrc compatiblc with thc cxistencc of a singlc 
rcceptor subtype. K i valucs wcrc calculatcd from IC ."o 
valucs using the Chcng and Prusoff (1973) equation. 
Tbc pKi values. prcscntcd in tablc I and figs. 2 and 3 
as means, wcrc defincd as -log Ki. Each cxpcrimcnt 
was repeated at least 3 timcs. Thc standard dcviation 
of cach IC 511 valuc was bclow 30% of thc avcragc valuc 
in all cascs (corrcsponding to pK i standard dcviations 
of < 0.1 log unit) and was thcrcforc not mcntioncd in 
tablc I and figs. 2 and 3. 
2.4. Dn1gs and chemieals 
r'H]N-methyl-scopolaminc ([-'H]NMS. 74 Cijmmol) 
was obtaincd from Amcrsham International (Bucks., 
UK). Atr,>pinc, polyethylcniminc and bovinc scrum 
albumin (Cohn fraction V) wcre obtaincd from Sigma 
Chemical Co. (St. Louis. MO. USA). Tissue culturc 
material and media wcrc ohtained from Gibco (Gent, 
Bclgium). All othcr chemieals wcrc of thc highcst 
grade availablc. 
Thc (R)- and (S)-cnantiomcrs uf trihcxyphcnidyl 
((R)-1 and (S)-1; as hydrochloridcs) (Schjcldcrup t:t al., 
1987) and trihexyphenidyl mcthiodidc ((R)-2 and (S)-2) 
(Schjcldcrup ct al., 1987 and unpublished rc~uits), pro-
cyclidinc ((R)-3 and (S)-3) (Tackc cl al., 1986), tricy-
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clamol iodide ((R)-4 and (S)-4) (Tackc ct al., 1986), 
hcxahydro-difcnidol ((R)-5 and (S)-5; as hydrochlo-
ridcs) (Tacke ct al., 1989), p-tluoro-hcxahydro-difen-
idol) ((R)-7 and (S)-7 as hydrochloridcs) (Strohmann ct 
al., 1991 ), p-tluoro-hcxahydro-difenidol methiodide 
((R)-8 and (S)~8) (Strohmann ct al., J 991), hcxbutinol 
((R)-9 and (S)-9) (Tackc ct al., 1989), hexbutinol me-
thiodidc ((R)~IO and (S)-10) (Fcifcl ct al., 1990), and 
p-tluoro-hcxbutinol (( R)-11 and (S)-11) (Strohmann ct 
al., 1991) and oxyphcncylimine ((R;-~3 and {S}·l~, as 
hydrochlorides) (Schjclderup ct al., 1988) were synthc-
sized according to thc literature. The (S)-enantiomer of 
p~fluoro-hcxbutinol methiodidc ((R)-12 and (S)-12) was 
also synthcsized according to thc Iiterature (Strohmann 
ct al.. 1991; in this papcr, the sign of thc optical 
rotation of (S)-12 is wrong; (S)-12 is not thc laevorota-
tory, but thc dextrorotatory enantiomer). 
Thc cnantiomers of hexahydro-difcnidol methiodidc 
((R)-6 and (S)-6) werc prcpar~d by quatcrnization of 
(R)-5 and (S)-5, respectively, with methyl iodide in 
acctone, following thc procedurc described for the 
synthcsis of (R)-8 and (S)-S (sec Strohmann et al., 
1991). 
(R)-6: C 22 H_,r)NO (457.4), yicld 84%, m.p. 138-
1390C (acctoncjdicUiyl cther, colourless needles), 
[a]~~6 = - 14 (c = 0.5. CHCI~), ec > 99.7%. Found: C, 
57.4; H, 8.3~ N, 3.0. Calculatcd: C, 57.77; H, 7.93; N, 
3.0fi. Structural charactcrization by 1 H and 1•1C NMR 
spcctroscopic studies (data not givcn). 
(S)-6: C22 H_~6 INO (457.4), yield 88%, m.p. 138-
1390C (acctoncjdicthyl cthcr, colourlcss ncedles), 
[a]~~6 = 14 (c = 0.5, CHCI_~), ce > 99.7%. Found: C, 
57.4; H, H.3; N, 3.0. Calculated: C, 57.77; H. 7.93; N, 
3.06. Structural charactcrization by 1 H and 1-'C NMR 
spcctroscopic studics {data not givcn). 
Thc (R)-cnantiomcr of p-fluoro-hcxbutinol mcthio-
didc ((R)-12) was prepared by quaternization of(R)-11 
pK, valucs of the (R)· and (S)·cnantiomcrs ur thc muscarinil" antagonists 1-U fur fuur muscarinic rcccptor suhtypcs. 
Muscarinic antagonist M1 (NB-OK I) M ~ (hcart) M ·' (pancrcas) M 4 (in striatum) 
No. (namc) (R)j(Sl (R)j(S) (R)j(S) (R)j(S> 
I (trihcxyphcnidyl) X.9j().5 7.7/fi.J X.l/5.5 X.Hjh.3 
2 (trihcxyphenidyl mcthiodidc> 9.6/7.-l X,(ljtl.lJ X.6/6.4 9.2;7.0 
3 (procyclidinc) X.4j6.2" 7.3j5.X '' 7.X/5.5 X. I /6.0 il 
4 (lricydamol indidc) 9.4jfl.9 X.3fo.6 X.6j5.1J K9j65 
5 (hcxahydm-difcnidoJ)" x.2;o.1 7.0j5.X K.Jj5.1J 7.9j6.0 
6 (hcxahydro-difcnidnl mcthiudiuc)" X.6/6.5 X.:!/6.0 X.l/5.5 KA/6.1 
7 ( p-tluoro·hcxahydro-difcnidnl) 7.9/5.9 h 6.1j5.tl h 7.9/5.~ 7.'1j5.X h 
R (p-tluoro-hcxahydro-difcnidol mcthiodidc) X.4/6.3 h 7.Hj5.<1 h X.2j6.:! K.2j6.2 to 
IJ (hcxbutinol) tttJj7.3 1Ulj7JI 9.3jH.2 
10 (hcxbutinol mcthiodidc X.Xji f1 10/7.4 '1.0j7.~ 
J I (p.fluoro-hcxbutinol) x.:!l .. :.o 7.~;7.1 H.4jH.3 
12 (p-nuoro-hcxhutinol mcthiodidc) ·: . .\/X.O 7.Hj7.5 S.4j7.H 
13 (oxyphcncycliminc) 9.0/7.5 K7j7.1 9.2;7.5 
n Data takcn from Waelhroeck ct al.. 1990h: ":Jata t<tkcn frnm Waclhrneck cl al.. J9tJJa. 
with methyl iodidc in acctonc, following the proccdurc 
described for the synthcsis of (S)-12 (see Strohmann et 
al., 1991). (R)-12: C.nHJ!F!NO (471.4), yicld 82%, 
m.p. (dcc.) l90°C (acetoncjdiethyl elher, colourlcss 
ncedles). [ag~6 = -2 (c '= 0.5, CHCI 3 ), ee > 99.8%. 
Found: C, 56.2; H. 6.5; N. 2.Q_ C:.tlc•llatcd: C, 56.06; H, 
6.63; N. 2.97. Structural charactcrization by 1 Hand uc 
NMR spectroscopic sturlies ( data not given). 
3. Results 
3.1. General considerations 
All the competition cutves obtained in this study 
were compatible with the existence of a single receptor 
subtype in thc different preparations with Hili coeffi-
cients not significantly different from unity (n 11 varied 
between 0.95 and 1.10, with Standard deviations below 
or cqual to 0.05). This suggestcd that [ 3 H]NMS la-
belled single bind!ng sites in each tissue or cell type. 
Competition cutves with (R)- anJ (S)-hexbutinol, 
(R)- and (S)-9 and (R)- and (S)-10-11 and -12 ana-
logues and oxyphencycliminc ((R)- and (S)-13) were 
shifted to the right by 0.5-l.O log units in all prepara-
tions in the presencc of l% bovine scrum albumin 
(data not shown). We therefore determincd thc bind-
ing affinities of the enantiomers of compounds 9-13 to 
muscarinic receptors in homogenates from human NB-
OK 1 cells, rat heart and striatum in the absence of 
bovint:: ~t::ruw albumin. pKi values are g:iven in table 1. 
The binuing properties of the (R)- and (S)-cnanti-
omers of p-üuoro-hcxahydro-difenidol (7) and its mc-
thiodide (8) to rat pancreas receptors wcre previously 
estimated by comparison of competition cutves in pan-
creas and brain cortex with 1% bovine serum albumin 
in the incubation buffer (see Materials and methods) 
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and in cortcx without bovine :-:.crum alhumin 
(Wadbrocck ct al.. 1991 a ). 
3.2. Receptur hinding profi/es of the ( R)- and (S)-cnanri-
omers 
As shown in table l, thc rcccptor binding profiles of 
the (R)- and (S)-cnantiomers of thc chiral drugs 1-13 
wcrc gcncrally diffeicnt. (R)-Trihexyphcnidyl ((R)-1 ), 
(R)-trihexyphcnidyl methiodide ((R)-2), (R)-procycli-
cLnc ((R)-3) and (R)-tricyclamol iodide ((R)-4) had a 
clear M 1 > M 2 sclcctivity, high affinitics for M 4 sitcs 
and intermediate or low affinities for the M_, sitcs. In 
contrast. their (S)-enan!iomers had an M1 > M 3 se:ec-
tivity. with intermediate affinities for the M 2 and M4 
sites. (R)-Hexahydro-difenidol ((R)-5) and (R)-p-flu-
oro-hexahydro-difenidol (( R)-7) had a preference for 
M 1, M 3 and M 4 over M 2 sites, while (S)-hexahydro-
difenidol and (S)-p-fluoro-hexahydro-difenidol were 
non-selective. (R)-Hexahydro-difenidol methiodide 
((R)-6) was almost non-selectivc. but (S}-hcxahydro-dif-
enidol methiodirte M 1 > M 3 preferring. (R}-Hexbutinol ((R)-9) was M 1, M 4 > M 2 prefcrring, but (S)-hcxbutinol 
((S)-9) sclective for M 4 over M 1 and ~ ... 12 sites. In 
cantrast with thesc results, th~ (R)- and (S)-cnanti-
omers of p-fluoro-hexbutinol (11) and p-fluoro-
hexbutinol methiodide ( 12) had the same selectivity for 
M 1, M 4 > M 2 sites. The (R)- and (S)-enantiomers of 
p-fluoro-hexahyriro-difenidoi methiodide (8), hexbuti-
nol methiodide ( 10) and oxyphen,~yclimine ( 13) were 
a1most non-selective. 
3.3. Stereosel:-ctirity at muscarinic receptors 
Thc (R)-enantiomers (cutomcrs) of compounds 1-13 
displaycd highcr affinities for M 1-M 4 receptors than 
thc (S)-isomers (distomers), the eudismic indcxes vary-
Eudismic indexes (differences betwccn the pKi valucs of thc (R)- and (S)-cnantiomcrs) of the antimuscarinics 1-13 at four muscarinic receptor 
subtypes. 
Muscarinic antagonist M 1 (Nß-OK)) M~ (hcart) M ·' (pancrcas) M4 <in slriatum) 
1 (trihexyphenidyl) 2.4 1.6 2.6 2.5 
2 ( trihexyphcnidyl methiodide) :!.2 1.7 2.2 2.:! 
3 (procyclidine) 2.1 1.5 .2.3 2.1 
4 (tricyclamol iodide) 2.5 1.7 '1.7 2.4 
5 (hcxahydro-difcnidol) 2.1 1.2 2.2 1.9 
6 (hexahydro-difenidol methiodidc) 2.1 2.2 2.6 2 .. \ 
7 (p-fluoro-hexahydro-difenidol) 2.0 1.1 2.1 2.1 
8 (p-fluoru hexahydro-difenidol mcthiodidc) 2.1 1.9 2.0 2.0 
9 (hexbutinol) J.(l 1.0 l.J 
JO ~hexbutinol methiodidc) 1.2 0.9 1.2 
II (p-fluoro-heKbutinol) 0.2 0.2 0.1 
12 (p·fluoro-hcxhutinol mcthiodidc) 0.3 lU n.o 
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Fig. 2. The eudismic indt!xes of thc phenyl compounds 0-6. 9. 10 
and 13) (circlcs) and the p-fluorophcnyl derivatives (7. 8. 11 and 12) 
{triangles) were plotted as a function of the cutomer affinity. The 
numbers identify thc compounds shown in fig. I and tablc I. and thc 
correlation lines are described in table 3. Top panel: M 1 rcccptors; 
bottom panel: M 2 receptors. 
ing by morc than two ot:dcrs of magnitudc. These 
observcd stercoselectivitic~• did not appcar to be associ-



























Fig. 3. As in fig. 2. Top panel: M-' receptors: hottom panel: M 4 
receptors. 
As shown in tablc 2, thc enantioselectivity ratios of 
compounds 1-5 and 7 consistently showed the same 
order: M 1 == M 3 = M ~ > M 2 • This implies that the 
stereochemical demands made by the muscarinic re-
ceptor subtypes were different for the enantiomers of 
compounds 1-5 and 7, being least stringent at M 2 
receptors. In contrast, thc cudismic indcxes for thc two 
Thc correlation lincs shown in figs. 2 and 3 can bc describcd as 'eudismic index = a + b (pK/ with the indicated values of ·a· and 'h' ". The 
correlation cocfficicnt r. and the probability (P) that thc slope is different from zcro are also indicated. 
Receptor Compound a b p 
subtype No. 
M, 1-+ 8 0.56 0.19±0.09 0.6H < 0.10 
Ml 2. 4. 9-13 -13.17 1.63 ± 0.13 0.9H < 0.02 
M2 
·-
8 -1.61 0.42±0.12 0.77 < 0.05 
M~ 2,9 +13 -8.06 J.ll ±0.26 0.95 < 0.05 
MJ 1-+ 8 0.46 0.23±0.32 0.26 n.s. h 
M" ]-+ 8 -0.34 0.30±0.1 J 0.72 < 0.05 
M.a 2. 9-+ 13 -12.14 1.49±0.59 0.82 <0.10 
a 'a' is thc eudismic index expected for a compound with a pKi = 0 (Ki \'aluc =I molar) and 'b', somctimes called 'cudismic affinity quotient', 
measures the slope of the line (i.e. the variation of stereoselectivity with affinity). h n.s. = not significant. 
methiodides 6 and 8 were very similar (1.9-2.6) at the 
four receptor subtypes. This was mainly based on the 
fact that N-methylation selectively increased the affin-
ity of the (R)-enantiomcrs of thc tcrtiary amines 5 and 
7 at M 2 receptors by more than one order of magni-
tude. 
The compounds 9-12 with a triple bond within the 
molecule had a lower eudismic index than the satu-
rated drugs 1-8 (table 2) at all subtypes studicd. The 
samc held true for oxyphencyclimine at M 1 anci M 4 
receptors. 
3.4. Correlation of tlze eutomer affinity and eudismk 
index 
We plotted in figs. 2 and 3 the eudismic index 
(difference between the pKi values of the (R)- and 
(S)-enantiomers) as a function of the affinity (pKi 
value) of the (R)-enantiomer (eutomer). We found no 
significant correlation between the affinity constants of 
either alt the eutomers or of all the unsubstituted 
eutomers 0-6, 9, 10, 13) and their eudismic indexes, 
at any subtype. Thanks to the presence of compounds 
11 and 12 in our set of data, we were able to subdivide 
the data into two groups (by visual inspection) for 
analysis. The eudismic index of compounds 1-8 (table 
1) did not vary significantly with the eutorner pK i value 
at M 3 receptors, and increased slightly with the pK i 
value at M 1, M 2 and M 4 receptors. In contrast, the 
eudismic index of compounds 4, 9-13 and (at M 1 
receptors only) 2 varied at least as much as the pKi 
value of the eutomer, at M 1, M 2 and M 4 receptors. 
The statistical parameters describing the regression 
lines (figs. 2 and 3) arc summarized in table 3. 
4. Discussion 
We investigate~ in this study the binding affinities of 
the enantiomers of oxyphencyclimine and of tertiary 
and quaternary compounds structurally relatcd to 
hexahydro-difenidol and hexbutinol at rnuscarinic M 1 
(NB-OK 1 cells), M 2 (rat heart), M 3 (rat pancreas) and 
M 4 receptors (rat striatum). Our main goals were to 
test the hypothesis that cudismic analysis data may be 
used in receptor classification and to obtain more 
inforrnation about the enantiomer-discriminating prop-
erlies of muscarinic receptor subtypes. 
4.1. Binding profile of the enantiomers and receptor 
classification 
The subtype selectiv!ty of most of the enantiomers 
studied depended on their absolute configuration. The 
(R)-enantiomers of compounds 1-13 bad a greater 
affinity for M 1-M 4 t('ceptors than the (S)-isomers (ta-
39 
bles 1 and 2). There was no rulc governing the relative 
binding pattern of the (R)- and (S)-enantiomcrs. For 
example: (R)-hcxahydro-difenidol ((R)-5) and (R)-p~ 
fluoro-hcxahydro-difenidol (( R )~ 7) had low affinitics 
for M 2 receptors (as compared to M 1, M 3 and M 4 
receptors), but (S)-5 and (S)-7 were non-selective. In 
contrast, the two enantiomers of hexbutinol methio-
dide (10), p-fluoro-hexbutinol (11), p-fluoro-hexbutinol 
methiodide (12) and m:yphencyclimine (13) had quali-
tatively the same binding pattern. (R)- and (S)-( 11) 
being M 1, M 4 > M 2 selective. 
Some of the enantiomer pairs studied are of special 
interest for receptor classification: for example. (R)-tri~ 
hexyphenidyl methiodide ((R)-2) and (R)-tricyclamol 
((R)-4) discriminated with thc highest selectivity M 1 
from M 2 receptors, but (S)-2 and (S)-4, M 1 from M 3 
receptors. (R)·Hexbutinol ((R)-9) discriminated M 1 and 
M 4 from M 2 receptors, but (S)-9 was M 4 preferring 
with a low affinity for M 2 and M 1 receptors. 
4.2. Stereoselective interaction with musca;inic receptors 
Four different groups are bound to the central car-
bon atom (centre of chirality) of the drugs {1-13) 
studied in this work: a protonated tertiary or a quater~ 
nary ammonium group, a hydroxyl moiety, a phenyl or 
p~fluorophenyl group, and a cyclohexyl group. Forma-
tion of an electrostatic interaction (protonated 
aminojammonium group) andjor hydrogen bond must 
be very important for binding: the cationic ammonium 
group and the hydroxyl group interact strongly with 
water when the drug is not bound. These interactions 
are disrupted when the drug reaches its binding site, 
and must therefore be replaced by strong interaction 
with the receptor. On the othcr hand, thc phcnyl and 
cyclohexyl groups do not interact favorably with water: 
dehydration per se is a favorable process. Binding can 
be further enhanced by close contact (van der Waals) 
interactions with the receptor, if the asymmetrically 
substituted carbon atom has the right absolute configu-
ration (Waelbroeck et al., 1990b, 1991 b ). 
We have previously analyzed the binding properties 
of the enantiomers of procyclidine (3) and hexahydro-
difenidol (5) and of structurally related achiral diphenyl 
and dicyclohexyl analogues (Waelbroeck et al., 1990b, 
1991b). Our results support the hypothesis that procy-
clidine and hexahydro-difenidol recognize four subsites 
of the muscarinic receptor, their stereoselectivity re-
flecting the stronger interaction of (R)-procyclidine 
((R)-3) or (R)·hexahydro-difenidol ({R)-5) and weaker 
interaction of (S)-3 or (S)-5 with the two hydrophobic 
subsites. 
Assuming that all the compounds studied here have 
the same binding pattern as procyclidine (3) and as-
suming that the ammonium groups of the two enan-
tiomers form the same type of ionic bond, wc expected 
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thc following results: (a) pairs of cnantiomcrs diffcring 
only in the structure of thcir amino (ammonium) groups 
should have thc samc cudismic indcx, at a ccrtain 
rcceptor subtypc; (b) the phcnyl group of the (R)- and 
(S)-enantiomcrs rccognizc, rcspectivcly, a phcnyl-prc-
fcrring and a cyclohexyJ .. prcfcrring subsitc (Waclbrocck 
ct al., l990b, l99Jb). p-Fiuoro suhstitution might thcrc-
fore affcct diffcrcntly thc affinity of thc two cnan-
tiomcrs and, as a rcsult, changc thc cudismic indcx of 
thc compounds. All p-tluoro derivatives, as a group, 
should however havc thc samc cudismic indcx at a 
particular subtype. 
Some of our experimental results wcrc in good 
agreemcnt with thcsc prcdic\i!.'OS. There was littlc if 
any variation of the cudismic index of muscarinic M 1• 
M 3 and M 4 rcceptors, for · procyclidine-likc deriva-
tives' (compounds 1-K tablc 2). However, differcnccs 
in eudismic indcxes for compounds 1-H wcre obscrvcd 
at M.:! receptors (tablcs I and 2). This supportcd thc 
hypoihcsis that thc ionic bond bctwccn thc anionic 
subsitc of thc rcccpmr and thc cationic hcad of thc 
cnantiomers of thc muscarinic antagonists ( 1-8) is in-
dcpcndent of thc drugs· absolute configuration, at least 
at M 1, M 3 and M" rcccptors. p-Fiuoro substitution 
affected markcdly thc cudismic indcx of hexbutinol (9) 
and of hexbutinol methiodidc (10): thc phcnyl rings 
sccmcd to rccognizc a different rcgion of thc reccptor, 
depcnding on the absolute configuration of thc drug, 
and this was littlc affected by N-mcthylation. 
On thc other hand: (a) N-rncthylation of hexa-
hydro-difenidol {5-.. 6) and of p-fluoro-hcxahydrD-
difenidol (7-+ 8) incrcased thc affinity of thc (R)- but 
not of the (S)-enantiomers for cardiac M 2 reccptors; 
(b} ihc cudismic indexcs of hexbütinol {9}, hcxbütino! 
methiodide ( 10) and oxyphencycliminc ( 13) wcrc signif-
icantly lowcr than thc cudismic indcxcs of thc com-
pounds 1-8 at M 1 and M~ rcccptors; (c) p-fluoro 
substitution of hexahydro-difcnidol (5), hcxahydro-
difcnidol mcthiodidc (6), hexbutinol (9) and hcxbutinol 
mcthiodidc (10) did not similarly affect thc binding 
properties of the four (R)- and (S)-enantiomcrs. 
To account for thcsc discrcpancics, wc would likc to 
suggcst that thc position and conformation of cach 
compound within thc reccptor can bc adjusted to 
achievc an optimal overall frec cncrgy change. Whcn 
comparing thc enantiomcrs of procyclidinc (3) and 
tricyclamol (4), or trihexyphenidyl (I) and its methio-
didc 2, for example, this is not a problcm: thesc com-
pounds are quitc similar in sizc and flcxibility and 
probably rccognizc thc samc rcgion in thc muscarinic 
binding sitc. ln contrast, thc cnantiomcrs of hcxahy-
dro-difcnidol (5), hexbutinol (9), thcir mcthiodidcs 6 
and 10 and oxyphcncyclimine ( 13) arc greatcr in size 
andjor morc rigid moleculcs: oncc thc ionic bond 
between thc amino (ammonium) group and the anionic 
subsite of the rcceptor is formed the chiral centers of 
(R)· and (5)-5, 6. 9, 10 and 13 might be unable to reach 
thc same position as (R)- and (S)-procyclidinc. rcspec-
tivcly. If. as a rcsult. thc two hydrophobic cyclcs of 
J -13 come in contact with different rcgions of a largc 
hydrophobic surfacc in thc musetuinie binding site, wc 
would cxpect: (a) different cudismic indexcs; and (b) 
different effccts of p-fluoro ~uhstitutinn on thc binding 
propcrtics of thc 'procyclidine-Iikc' drugs ( 1-8) and 
'hcxbutinol-likc' drugs (9-13). 
4.3. App/ication of Pfeiffer:'l· rufe mzd o.f its corollary 
lt is often suggcsted (Lchmann, 1986) that the eu-
dismic indcx increases linearly with eutomer potency, 
not only whcn comparing a series of rclatcd drugs 
interacting with a single rcceptor (this is known as 
• Pfciffcr's rulc ') but also whcn comparing thc interac-
tion of a singlc pair of enantiomcrs with scvcral differ· 
cnt reccptors or rcceptor subtypcs. As cxplained by 
Bürlow ( 1990), it is plausible that the !1ighcr the affinity 
of thc eutomcr of a chiraJ compot;nd, thc more it 
mattcrs how groups arc arrangcJ about thc cc~tre of 
chirality. This cxplains that. as a rule, thc cudismic 
indcx associatcd with chir:al drugs having a high affinity 
for the eutomer is largcr. Finding a linear corrciation 
between cutomcr affinity and eudismic indcx ls, how-
cvcr, far lcss likely: tlcxih~c molcculcs might hav~ 
grcatcr affini{!cs and lowcr cudismic indcxcs than morc 
rigid molcculcs, simply because both enantiomcrs are 
capablc of adapting their conformations to achievc a 
bctter fit with thc reccptors. \Ne cxpcctcd that finding 
a linear corrclation bctwecn cudismic index and affin-
ity for a sei of molcculcs would givc valuable informa-
tion about !hc drug-hinding piroccss. ln ord~r to tcst 
this hypothesis. wc rcprcscnted our data in figs. 2 and 
3 and attcmptcd to find a corrclation bctwccn eudis-
mic indcx and cutomcr affinity, cithcr for all com-
pounds or for separate sets of thc drugs. We found 
good correlations when grouping compounds 1 -.. 8 
and compounds (2) 4. 9-+13 in M 1, M2 and M 4 
rcccptors (tablc 3). 
Most of thc compounds in thc first group diffcr in 
thcir ammonium (protonatcd amino) group. Thc 
'eudismic affinity quoticnt' (slope of the regression 
line) was small: thc affinitics of thc (R)- and of the 
(S)-cnantiomcrs varied in parallel. This is in good 
agrccmcnt with our hypothesis that the ionic bond is 
essential for binding of both enantiomers. Two p-flu-
oro derivatives 7 and 8 also fell in this group. As 
discussed abovc, we belicvc that. in order to allow the 
hydrogen bindings of thc OH group and the ionic 
intcractions of the ammonium moietics. thc phenyl 
group of (R)-hexahydro-difenidol ((R)-5) and (S)-5 rec-
ognizc different rcgions of the rcceptor, and that, by 
chance, p-fluoro substitution induced thc samc affinity 
loss at both subsites. 
Thc sccond group includcd hexhutinol (9) deriva-
tives and oxyphencyclimine ( 1 3), as weil as tricyclamol 
iodidc (4) and (in M 1 rcccptors) trihcxyphenidyl mc-
thiodidc (2). Thc cudismic indcx of thcsc drugs in-
creased markedly with cutomer affinity. 
Wc wcre not surprist'J to find in the sccond group 
hexbutinol (9) and its mcthiodidc ( 10) and thc p-tluoro-
substitutcd derivatives 11 and 12. lndccd, if thc phcnyl 
rings of thc (R)- and (S)-configuratcd drugs rccognizc 
different sitcs in thc muscarinic rcccptor. p-tluoro sub-
stitution may afiect diffcrently the binding properlies 
of cach enantiomcr, and changc thc cudismic indcx 
(tablc 2). On thc othcr hand, wc did not cxpcct to find 
in thc same group cxyphcncycliminc ( 13), tri-
hexyphenidyl mcthiodidc {2) and tricyclamol iodidc (4) 
which diffcr from hcxbutinol (9) by their ammonium 
(protonated amino) group. 
We would likc to suggcst that thc protonatcd amino 
group of thc cnantiomers of hexbutinol (9) and 
oxyphencydiminc ( 13) forms ionic honds with an aspar-
tatc rcsiduc of thc rcccptor. Duc to stcric hindrancc, 
thc positions of the asymmctricaJly substituted carhon 
atoms of, for cxamplc, the hcxbutinol or oxyphcncy· 
climinc enantiomcrs arc, thus. not idcntical with thosc 
of thc tricyclamol cnantiomcrs. 
In conclusion: using pure cnantiomcrs rather than 
raccmic mixturcs can bc hclpful for rcccptor classifica· 
tion (thc cudismic indcxcs may scrve as an additional 
criterium for rcccptor subtype identification. and •he 
binding pattcrn of thc two enantiomcrs is somctimes 
vcry different). Corrclations betwccn thc eudismic in-
dcx and high-affinity cnantiomcr potcncy. whcn prcs-
cnt. should howcvcr bc intcrprcted only with thc grcatft 
e~t caution. 
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